Daiichi Sankyo invests $1B to bulk out German site for cancer ADCs
Daiichi Sankyo is pouring €1 billion ($1.07 billion) into a German facility in part to expand its capacity for antibody-drug conjugate manufacturing. The first part of the expansion became operational last month, a company spokesperson told Endpoints News.
The facility is in Pfaffenhofen an der Ilm, which is a 40-minute drive north of Munich. The Japanese pharma will build a new lab for cancer ADCs that will be finished by 2026 in addition to bolstering cardiovascular disease asset production. There is “increased global demand for ADC cancer therapies,” added Daiichi Europe site manager Matthias Kühn in the press release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.